Neuland Laboratories Ltd Share Price
As on 13 June 2026 at 02:40 IST
Neuland Laboratories Q1 FY26 Results:
Profit for the period declined by 85.7% to ₹14 crores in Q1 FY26, from ₹97.9 crores in Q1 FY25. Total income for the quarter decreased by 32.2% year-on-year to ₹300.6 crores, from ₹444.4 crores.
About Neuland Laboratories Ltd
Neuland Laboratories Limited, established in the year 1984, has carved out a significant niche in the pharmaceutical industry. Headquartered in the city of Hyderabad, India, the company specialises in the production of active pharmaceutical ingredients (APIs). Neuland's product portfolio spans both prime APIs (high-volume, mature molecules) and specialty APIs (lower-volume, complex molecules with less market competition). The company's strength lies in its ability to overcome challenging chemistry problems. While not the largest player in terms of market share or capitalization, Neuland Laboratories Limited has maintained a strong position in its sector. +
The Current prices are delayed, log in for live prices
LOGINOver 1 Month
-3.29%
Over 6 Months
4.93%
Over 1 Year
24.53%
Over 3 Years
472.07%
Neuland Laboratories Ltd Summary
Close ₹16,973
Open ₹16,800
High ₹17,239
Low ₹16,711
Volume 50,931
Net Turnover (in Cr) ₹86.93
52Wk High ₹19,747
52Wk Low ₹11,500
52Wk High / Low
11,500
19,747
Neuland Laboratories Ltd Fundamentals
Key Financial Data
Market Cap (in Cr) ₹21,776.17
EPS (TTM) 283.01
Book Value (BV) 1,453.59
Div. Yield 0.20 %
P/E (TTM) 59.90
Price/Book Value 11.66
Delivery % 55.61 %
Face Value 10
Key Ratios
PE Ratio 60.05
PB Ratio 10.27
EV to Sales 10.42
PEG Ratio -4.48
ROA 15.43
ROE 14.86
Debt-Equity 0.09
Net Profit Margin 14.05
Operating Profit Margin 23.71
Neuland Laboratories Ltd Financials
Profit and Loss
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Total Revenue | 1,497.35 | 1,571.12 | 1,200.95 | 953.15 | 953.01 |
| Total Expenses | 1,227.42 | 1,169.69 | 985.20 | 870.99 | 847.67 |
| Profit Before Tax | 346.33 | 401.44 | 215.75 | 82.16 | 105.33 |
| Profit After Tax | 260.11 | 300.08 | 163.52 | 63.82 | 80.63 |
| Operating Profit After Depreciation | 278.22 | 415.43 | 228.81 | 95.66 | 123.23 |
Balance Sheet
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Fixed Assets | 958.03 | 804.64 | 738.19 | 747.70 | 696.94 |
| Total Non Current Assets | 1,040.38 | 911.48 | 818.87 | 802.70 | 775.20 |
| Total Current Assets | 1,139.50 | 921.08 | 760.89 | 580.79 | 549.59 |
| Total Assets | 2,179.88 | 1,832.56 | 1,579.76 | 1,383.49 | 1,324.79 |
| Total Shareholder's Fund | 1,524.81 | 1,282.70 | 994.10 | 840.50 | 786.46 |
Cash Flow
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Net Cash From Operating Activities | 317.38 | 261.18 | 237.21 | 60.39 | 189.36 |
| Net Cash Used In Investing Activities | -297.99 | -149.74 | -61.09 | -95.45 | -84.47 |
| Net Cash Used In Financing Activities | 24.96 | -69.28 | -135.80 | 37.72 | -113.66 |
Profit and Loss
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Total Revenue | 1,497.35 | 1,571.12 | 1,200.95 | 953.15 | 953.01 |
| Total Expenses | 1,228.38 | 1,170.36 | 985.73 | 871.41 | 848.05 |
| Profit Before Tax | 345.37 | 400.77 | 215.21 | 81.74 | 104.96 |
| Profit After Tax | 259.43 | 299.60 | 163.12 | 63.53 | 80.29 |
| Operating Profit After Depreciation | 277.27 | 414.77 | 228.28 | 95.23 | 122.86 |
Balance Sheet
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Fixed Assets | 958 | 804.63 | 738.19 | 747.70 | 696.92 |
| Total Non Current Assets | 1,040.35 | 911.46 | 819 | 802.87 | 775.34 |
| Total Current Assets | 1,137.82 | 919.47 | 760.34 | 579.25 | 548.18 |
| Total Assets | 2,178.17 | 1,830.93 | 1,579.34 | 1,382.12 | 1,323.52 |
| Total Shareholder's Fund | 1,517.79 | 1,276.54 | 988.36 | 835.57 | 781.88 |
Cash Flow
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Net Cash From Operating Activities | 317.49 | 260.06 | 238.53 | 60.41 | 189.28 |
| Net Cash Used In Investing Activities | -298.14 | -149.67 | -61.50 | -95.53 | -84.42 |
| Net Cash Used In Financing Activities | 24.96 | -69.28 | -135.80 | 37.72 | -113.66 |
| Particulars (in ₹ Cr.) | 2026-03 | 2025-12 | 2025-09 | 2025-06 | 2025-03 |
|---|---|---|---|---|---|
| Total Revenue | 776.25 | 439.71 | 514.27 | 292.75 | 328.36 |
| Total Expenses | 468.92 | 362.58 | 358.73 | 258.26 | 277.29 |
| Profit Before Tax | 287.49 | 54.47 | 129.43 | 17.58 | 39.29 |
| Profit After Tax | 212.67 | 40.57 | 96.85 | 13.90 | 27.81 |
| Operating Profit after Depreciation | 319.79 | 85.18 | 157.34 | 42.35 | 58.53 |
| Particulars (in ₹ Cr.) | 2026-03 | 2025-12 | 2025-09 | 2025-06 | 2025-03 |
|---|---|---|---|---|---|
| Total Revenue | 776.25 | 439.71 | 514.27 | 292.75 | 328.36 |
| Total Expenses | 469.34 | 362.78 | 359.15 | 258.46 | 277.61 |
| Profit Before Tax | 287.05 | 54.27 | 129.04 | 17.38 | 38.97 |
| Profit After Tax | 212.52 | 40.42 | 96.46 | 13.71 | 27.73 |
| Operating Profit after Depreciation | 319.37 | 84.98 | 156.92 | 42.15 | 58.21 |
Neuland Laboratories Ltd Technicals
Support and Resistance
S3 S2 S1 Pivot R1 R2 R3
S1 16,709.67
S2 16,446.33
S3 16,181.67
Pivot 16,974.33
R1 17,237.67
R2 17,502.33
R3 17,765.67
Moving Average
20 SMA 16,846.20
50 SMA 15,695.42
100 SMA 14,365.55
200 SMA 15,023.75
Neuland Laboratories Ltd Corporate Actions
Neuland Laboratories Ltd
₹12.0/Share
Announcement Date 18 Jul 2025
Record Date 18 Jul 2025
Div Yield 120%
Neuland Laboratories Ltd Peer Comparison
| Company | Price | Market Cap (in Cr) |
|---|---|---|
| Sun Pharmaceutical Industries Ltd | ₹1,794.30 | ₹4,30,512.67 |
| Divis Laboratories Ltd | ₹6,651.25 | ₹1,76,569.79 |
| Torrent Pharmaceuticals Ltd | ₹4,570 | ₹1,54,669.57 |
| Cipla Ltd | ₹1,383 | ₹1,11,725.01 |
| Zydus Lifesciences Ltd | ₹1,105.65 | ₹1,11,254.26 |
Neuland Laboratories Ltd Top Mutal Funds Invested
| Fund Name | AUM |
|---|---|
| Mahindra Manulife Small Cap Fund | 2.56% |
| Mahindra Manulife Multi Cap Fund | 2.41% |
| Mirae Asset Small Cap Fund | 2.09% |
| Sundaram Small Cap Fund | 2.08% |
| ICICI Pru Flexicap Fund | 2% |
Neuland Laboratories Ltd News
Neuland Laboratories board approves capacity additional at Unit 1
At meeting held on 12 May 2026
12 May 2026, 07:34 pm
Neuland Laboratories board appoints director
At meeting held on 12 May 2026
12 May 2026, 07:33 pm
Neuland Laboratories to convene AGM
On 4 August 2026
12 May 2026, 04:43 pm
Board of Neuland Laboratories recommends final dividend
Of Rs 34 per share
12 May 2026, 04:32 pm
Neuland Laboratories to conduct board meeting
On 12 May 2026
21 Apr 2026, 10:21 am
Neuland Laboratories Ltd Stock Analysis
- Annual revenue for Neuland Laboratories Ltd decreased by 4.70% to ₹1,497.35 crore in FY 2025 from ₹1,571.12 crore in FY 2024.
- Annual Net Profit for Neuland Laboratories Ltd decreased by 13.41% to ₹259.43 crore in FY 2025 from ₹299.60 crore in FY 2024.
- Promoter Shareholding in Neuland Laboratories Ltd remains unchanged by 0.00% in the most recent quarter, from 32.63% in December 2025 to 32.63% in March 2026.
- Neuland Laboratories Ltd delivered a 1-year return of 24.53% compared to the Nifty 50, which provided a return of -7.87% as of the last trading session.
- Neuland Laboratories Ltd share price moved up by 1.12% from its previous close of INR ₹16,973. The latest Neuland Laboratories Ltd share price is INR ₹17,163.
- Neuland Laboratories Ltd share price today has been at a low of 17,056 and a high of 17,400. Over the past 52 weeks, the Neuland Laboratories Ltd share price has seen a low of 11,500 and a high of 19,747.
About Neuland Laboratories Ltd
Neuland Laboratories Limited, established in 1984, has carved out a significant niche in the pharmaceutical industry. Headquartered in Hyderabad, India, the company specialises in the production of active pharmaceutical ingredients (APIs). It also offers custom manufacturing solutions and peptide synthesis services.
A key aspect of Neuland's ownership structure is the substantial promoter shareholding. It reflects the founding family's ongoing commitment to the company's success. Dr. D. R. Rao owns a 21.59% stake in the company. Under his family's leadership, Neuland Laboratories has developed a reputation for expertise in complex API development and production. There are also some managerial promoters who have contributed to the company's success. They are ● Nirmala Murthy ● Prasad Raghava Menon ● Pallavi Joshi Bakhru ● Christopher M Cimarusti ● Homi Rustum Khusrokhan Neuland's product portfolio spans both prime APIs (high-volume, mature molecules) and specialty APIs (lower-volume, complex molecules with less market competition). The company's strength lies in its ability to overcome challenging chemistry problems. While not the largest player in terms of market share or capitalization, the company has maintained a strong position in its sector.
The registered office is located in Hyderabad, Telangana. Meanwhile, Neuland’s registrars are in the Financial District. The company is publicly traded, with listings on the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE). Throughout its history, Neuland Laboratories has demonstrated a consistent focus on quality. These attributes have allowed the company to maintain its competitive edge. It has also helped it grow in the dynamic pharmaceutical sector.
Early Years and Foundation Neuland Laboratories was established by Dr. D. R. Rao, a visionary with a deep understanding of the pharmaceutical industry. The company started with a focus on producing APIs, which are the essential components of any drug. From the beginning, Neuland emphasised quality and compliance. It helped ensure its products met stringent international standards. This commitment to quality helped the company gain the trust of clients and regulatory bodies worldwide.
Growth and Expansion In its early years, Neuland Laboratories focused on developing a robust portfolio of APIs. The company invested in state-of-the-art manufacturing facilities and advanced analytical laboratories. This infrastructure enabled Neuland to produce high-quality APIs for various therapeutic areas. As the demand for APIs grew, Neuland expanded its production capacity and entered new markets.
Strategic Shifts and Innovations The pharmaceutical industry is highly competitive. Neuland Laboratories recognized the need to innovate and adapt to changing market dynamics. In 2021, the company made a strategic shift towards custom manufacturing solutions (CMS). This move was driven by the increasing demand for specialised APIs tailored to meet the unique requirements of pharmaceutical companies. The company was able to offer high-margin, high-value services that set it apart from competitors by focusing on CMS.
Custom Manufacturing Solutions Custom manufacturing involves producing APIs for specific drugs under development by pharmaceutical companies. This requires a high level of expertise and flexibility, as each project has unique challenges and requirements. Neuland Laboratories excelled in this area by leveraging its extensive experience. The company’s CMS business grew rapidly, contributing to its revenue and profitability.
Technological Advancements Neuland Laboratories has always been at the forefront of technological advancements in the pharmaceutical industry. The company invests heavily in research and development (R&D) to enhance its manufacturing processes and develop new APIs. Neuland’s R&D team works on innovative solutions to improve drug efficacy and reduce production costs. This focus on technology and innovation has helped Neuland maintain its competitive edge.
Quality and Compliance Quality and compliance are the cornerstones of Neuland Laboratories’ operations. The company adheres to stringent quality control measures at every stage of the manufacturing process. Neuland’s facilities are regularly audited by regulatory authorities such as the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the World Health Organization (WHO). These audits ensure that Neuland’s products meet the highest standards of safety.
Global Presence Neuland Laboratories has a strong global presence, with clients in over 80 countries. The company’s APIs are used by leading pharmaceutical companies worldwide. Neuland’s global reach is supported by its strategic partnerships with other industry leaders. These collaborations enable Neuland to stay ahead of market trends and deliver innovative solutions.
Challenges and Resilience Like any company, Neuland Laboratories has faced its share of challenges. The pharmaceutical industry is subject to stringent regulations and fluctuating market conditions. However, Neuland’s resilience and adaptability have helped it navigate these challenges successfully. The company’s strategic focus on high-value services and quality assurance has been key to its sustained growth and success. Overall, Neuland Laboratories’ journey is a testament to its commitment to quality, innovation, and customer satisfaction.
A key aspect of Neuland's ownership structure is the substantial promoter shareholding. It reflects the founding family's ongoing commitment to the company's success. Dr. D. R. Rao owns a 21.59% stake in the company. Under his family's leadership, Neuland Laboratories has developed a reputation for expertise in complex API development and production. There are also some managerial promoters who have contributed to the company's success. They are ● Nirmala Murthy ● Prasad Raghava Menon ● Pallavi Joshi Bakhru ● Christopher M Cimarusti ● Homi Rustum Khusrokhan Neuland's product portfolio spans both prime APIs (high-volume, mature molecules) and specialty APIs (lower-volume, complex molecules with less market competition). The company's strength lies in its ability to overcome challenging chemistry problems. While not the largest player in terms of market share or capitalization, the company has maintained a strong position in its sector.
The registered office is located in Hyderabad, Telangana. Meanwhile, Neuland’s registrars are in the Financial District. The company is publicly traded, with listings on the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE). Throughout its history, Neuland Laboratories has demonstrated a consistent focus on quality. These attributes have allowed the company to maintain its competitive edge. It has also helped it grow in the dynamic pharmaceutical sector.
Neuland Laboratories’ Journey in Pharma
Neuland Laboratories Limited, founded in 1984, has carved a niche for itself in the pharmaceutical industry. The company specialises in the manufacturing and sale of active pharmaceutical ingredients (APIs). It also offers custom manufacturing solutions and peptide synthesis services. Over the years, Neuland has built a reputation for quality and reliability, making significant contributions to the global pharmaceutical landscape.Early Years and Foundation Neuland Laboratories was established by Dr. D. R. Rao, a visionary with a deep understanding of the pharmaceutical industry. The company started with a focus on producing APIs, which are the essential components of any drug. From the beginning, Neuland emphasised quality and compliance. It helped ensure its products met stringent international standards. This commitment to quality helped the company gain the trust of clients and regulatory bodies worldwide.
Growth and Expansion In its early years, Neuland Laboratories focused on developing a robust portfolio of APIs. The company invested in state-of-the-art manufacturing facilities and advanced analytical laboratories. This infrastructure enabled Neuland to produce high-quality APIs for various therapeutic areas. As the demand for APIs grew, Neuland expanded its production capacity and entered new markets.
Strategic Shifts and Innovations The pharmaceutical industry is highly competitive. Neuland Laboratories recognized the need to innovate and adapt to changing market dynamics. In 2021, the company made a strategic shift towards custom manufacturing solutions (CMS). This move was driven by the increasing demand for specialised APIs tailored to meet the unique requirements of pharmaceutical companies. The company was able to offer high-margin, high-value services that set it apart from competitors by focusing on CMS.
Custom Manufacturing Solutions Custom manufacturing involves producing APIs for specific drugs under development by pharmaceutical companies. This requires a high level of expertise and flexibility, as each project has unique challenges and requirements. Neuland Laboratories excelled in this area by leveraging its extensive experience. The company’s CMS business grew rapidly, contributing to its revenue and profitability.
Technological Advancements Neuland Laboratories has always been at the forefront of technological advancements in the pharmaceutical industry. The company invests heavily in research and development (R&D) to enhance its manufacturing processes and develop new APIs. Neuland’s R&D team works on innovative solutions to improve drug efficacy and reduce production costs. This focus on technology and innovation has helped Neuland maintain its competitive edge.
Quality and Compliance Quality and compliance are the cornerstones of Neuland Laboratories’ operations. The company adheres to stringent quality control measures at every stage of the manufacturing process. Neuland’s facilities are regularly audited by regulatory authorities such as the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the World Health Organization (WHO). These audits ensure that Neuland’s products meet the highest standards of safety.
Global Presence Neuland Laboratories has a strong global presence, with clients in over 80 countries. The company’s APIs are used by leading pharmaceutical companies worldwide. Neuland’s global reach is supported by its strategic partnerships with other industry leaders. These collaborations enable Neuland to stay ahead of market trends and deliver innovative solutions.
Challenges and Resilience Like any company, Neuland Laboratories has faced its share of challenges. The pharmaceutical industry is subject to stringent regulations and fluctuating market conditions. However, Neuland’s resilience and adaptability have helped it navigate these challenges successfully. The company’s strategic focus on high-value services and quality assurance has been key to its sustained growth and success. Overall, Neuland Laboratories’ journey is a testament to its commitment to quality, innovation, and customer satisfaction.
FAQ’s
What is the share price of Neuland Laboratories Ltd today?
Neuland Laboratories Ltd share price as on 12 Jun 2026 is ₹ 17163.0
What is the Market Cap of Neuland Laboratories Ltd?
The market cap of Neuland Laboratories Ltd stock is ₹21,776.17 Cr.
What is the PE Ratio of Neuland Laboratories Ltd?
The Price to Earnings (P/E) Ratio of Neuland Laboratories Ltd is 60.05
What is the PB Ratio of Neuland Laboratories Ltd?
The Price to Book (P/B) Ratio of Neuland Laboratories Ltd is 10.27
What is the 52 week high of Neuland Laboratories Ltd Share Price?
The 52 week high of Neuland Laboratories Ltd share price stands at ₹19,747
What is the 52 week low of Neuland Laboratories Ltd Share Price?
The 52 week low of Neuland Laboratories Ltd share price stands at ₹11,500
How can I buy shares of Neuland Laboratories Ltd?
Simply open a demat account with Torus Digital and place an order to buy shares of Neuland Laboratories Ltd.
Open FREE
3-in-1 Account
for all your banking, trading and demat needs
Trade in stocks,
derivatives and F&O
